Comparative Pharmacology
Head-to-head clinical analysis: MEPRIAM versus MEPROSPAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MEPRIAM versus MEPROSPAN.
MEPRIAM vs MEPROSPAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mepriam is a thiazide-like diuretic that inhibits the Na+-Cl- symporter in the distal convoluted tubule, reducing reabsorption of sodium and chloride, leading to increased diuresis and vasodilation.
Meprobamate is a carbamate derivative that acts as a central nervous system depressant. It potentiates GABA-A receptor activity and inhibits excitatory neurotransmitter release, leading to anxiolytic, sedative, and muscle relaxant effects.
Adults: 500 mg IV every 24 hours.
Meprobamate: 400-600 mg orally 3-4 times daily, maximum 2400 mg/day.
None Documented
None Documented
The terminal elimination half-life of MEPRIAM is 12–15 hours (mean 13.5 h) in healthy adults, allowing once-daily dosing. In severe renal impairment (CrCl <30 mL/min), half-life may extend to 30–40 hours, requiring dose adjustment.
Terminal elimination half-life: 15 hours. Steady state reached after 3-5 days. No active metabolites.
MEPRIAM is predominantly eliminated via renal excretion (approximately 85% as unchanged drug and metabolites) and about 15% via fecal/biliary routes. Renal clearance accounts for ~70% of total clearance.
Renal: 70% as inactive metabolites; fecal: 20% as conjugated metabolites; biliary: 10%.
Category C
Category C
Anxiolytic
Anxiolytic